The 2023 HIV Cure & Immunotherapy Forum, organized by the IAS Towards an HIV Cure initiative, will be held at the Brisbane Convention & Exhibition Centre in Brisbane, Australia, on 22 July 2023 alongside IAS 2023, the 12th IAS Conference on HIV Science. The content of the Forum will be accessible online after the meeting.
The Forum will feature invited speakers, oral abstract discussions, a poster exhibition and a panel discussion. A networking reception will be held to facilitate further discussion.
Objectives
- Accelerate research on immunotherapy curative strategies.
- Create an environment to foster interdisciplinary collaborations and merge the HIV cure and immunotherapy disciplines.
- Provide an opportunity for the next generation of investigators to launch their careers through interaction and discussion with peers.
- Promote engagement of researchers, advocates, social and behavioural scientists, ethicists, philanthropic organizations and the private sector and seek to promote research in low- and middle-income settings.
- Promote increased investments in cure research.
- Provide a platform for information sharing, debate and networking among peers.
Programme committee
- Thumbi Ndung'u, Africa Health Research Institute, Durban, South Africa, co-chair
- Beatriz Mothe Pujadas, IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Spain, co-chair
- Anthony Kelleher, Kirby Institute, University of New South Wales, Australia co-chair
- Heather Ellis, Positive Women Victoria, Australia
- Sharon Lewin, Doherty Institute, Melbourne University, Australia
- Steven Deeks, University of California San Francisco, United States
Programme
| 07:30 – 08:30 | Registration | |
| 08:30 – 09:20 | Opening | |
| 08:30 – 08:50 | Welcome and Introduction | Towards an HIV Cure Initiative co-chairs:
Welcome from community representative:
Programme committee co-chairs:
|
| 08:50 – 09:20 | Keynote Lessons learnt from immunotherapy for autoimmunity |
Ranjeny Thomas, University of Queensland, Australia |
| 09:20 – 10:45 | Session 1 – bNAbs and combination studies | |
| 09:20 – 09:25 | Introduction to the session | David O’Connor, University of Wisconsin-Madison, United States |
| 09:25 – 09:45 | Invited talk Clinical trials using bNAbs |
Ming Lee, Imperial College London, United Kingdom |
| 09:45 – 10:05 | Invited talk Combination ATI trials |
Michael Peluso, University of California San Francisco, United States |
| 10:05 – 10:15 | Flash talk How to integrate reservoir measurements in ATI cure trials |
Tokameh Mahmoudi, Erasmus University, The Netherlands |
| 10:15 - 10:25 | Flash talk Clinician and participant perspectives on ATI in clinical trials |
Jillian Lau, The Peter Doherty Institute, Australia |
| 10:25 - 10:35 | Oral abstract Effect of combination latency reversing agents and bNAb in SHIV-infected rhesus macaques on antiretroviral therapy |
Binhua Ling, Texas Biomedical Research Institute, United States |
| 10:35 – 10:45 | General discussion | Moderator: Marina Caskey, The Rockefeller University, United States |
| 10:45 – 11:05 | Coffee break | |
| 11:05 – 12:40 | Session 2 – Vaccines and immunotherapies | |
| 11:05 - 11:10 | Introduction to the session | Jean-Pierre Routy, McGill University, Canada |
| 11:10 – 11:30 | Invited talk HTI T-cell vaccine clinical trials |
Beatriz Mothe Pujadas, IrsiCaixa, Spain |
| 11:30 – 11:50 | Invited talk Immunotherapies in acute cohorts |
Julie Ake, US Military HIV Research Program |
| 11:50 – 12:00 | Flash talk Immunotherapies in non-human primates |
Afam Okoye, Oregon National Primate Research Center, United States |
| 12:00 - 12:10 | Flash talk Vaccination against PD1 |
Zhiwei Chen, The University of Hong Kong, China |
| 12:10 - 12:20 | Oral abstract Favourable transcriptomic signature of HIV-specific CD8 T cells in response to single anti-PD1 dose in people with HIV on ART and cancer |
Jan Schroeder, Peter Doherty Institute, Australia |
| 12:20 – 12:30 | Oral abstract Ruxolitinib-mediated HIV-1 reservoir decay in A5336 phase 2a trial |
Monica D. Reece, Emory University, United States |
| 12:30 – 12:40 | General discussion | Moderator: Gabriela Turk, CONICET, Argentina |
| 12:40 – 14:00 | Lunch break | |
| 14:00 – 15:15 | Session 3 – Gene and cell therapy | |
| 14:00 - 14:05 | Introduction to the session | Chantelle Ahlenstiel, Kirby Institute, Australia |
| 14:05 – 14:15 | Flash talk CCR5 bnAbs and monkeys |
Jesse Deere, University of California, Davis, United States |
| 14:15 – 14:25 | Flash talk R5 breakthrough after a successful CCR5-delta 32 stem cell transplant |
Eli Boritz, National Institutes of Health, United States |
| 14:25 – 14:35 | Flash talk Adeno-associated viruses (AAVs) for delivery of anti-HIV antibodies |
Ann Chahroudi, Emory University, United States |
| 14:35 - 14:45 | Oral abstract Potent, HIV-specific latency reversal through CRISPR activation delivered by lipid nanoparticles exhibiting a high efficiency of transfecting resting CD4+ T cells with minimal toxicity |
Paula M. Cevaal, Peter Doherty Institute, Australia |
| 14:45 - 14:55 | Oral abstract The Effects of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) and Vorinostat on Persistent HIV-1 in People Living with HIV on Antiretroviral Therapy |
David Michael Margolis, University of North Carolina at Chapel Hill, United States |
| 14:55 – 15:05 | Oral abstract Engineering macaque B cells for persistent anti-HIV broadly neutralizing antibodies production |
Anne-Sophie Kuhlmann, Fred Hutchinson Cancer Center, United States |
| 15:05 – 15:15 | General discussion | Moderator: Kara Chew, University of California, Los Angeles, United States |
| 15:15 – 15:35 | Coffee break | |
| 15:35 – 16:40 | Session 4 – Mechanisms of post-treatment and post-intervention control | |
| 15:35 - 15:40 | Introduction to the session | Michaela Muller-Trutwin, Institut Pasteur, France |
| 15:40 - 15:50 | Invited talk Antigen-specific NK cells as a potential mechanism for virus control? |
Keith Reeves, Duke University, United States |
| 15:50 - 16:10 | Flash talk Mechanisms for post-intervention control |
Sarah Palmer, University of Sydney, Australia |
| 16:10 - 16:20 | Flash talk Post-treatment control in non-human primates |
Shelby O’Connor, University of Wisconsin School of Medicine and Public Health, United States |
| 16:20 - 16:30 | Oral abstract Post-treatment controllers exhibit distinct CD8+ T cell features before and after ART interruption |
Tongcui Ma, Gladstone Institutes, United States |
| 16:30 - 16:40 | General discussion | Moderator: Alan Landay, Rush University, United States |
| 16:40 – 17:25 | Session 5 – Panel Discussion: Community Engagement and the Importance of a Diversified Study Population for Cure Studies | |
| 16:40 - 16:45 | Introduction to the session | Steven Deeks, University of California San Francisco, United States |
| 16:45 - 17:25 | Panel discussion | Panelists:
Moderator:
|
| 17:25 – 17:33 | Session 6 | |
| 17:25 – 17:33 | Considerations on Language Use for HIV Cure Research | Michael Louella, DARE CAB, United States Moderator:
|
| 17:33 - 17:55 | Report-back session from rapporteurs | |
| 17:55 - 18:05 | Closing remarks | |
| 18:05 - 19:00 | Poster exhibition and networking session | |
Sign up to participate
To encourage the broadest participation in the pre-meeting, attendance will be free. However, the meeting will be in person only and limited to 300 attendees. Please note you may only sign up for one IAS 2023 pre-meeting.
Event at capacity and registration is closed. Add your name to the waiting list by emailing hivcure@iasociety.org.
Please note that signing up for the pre-meeting does not grant you access to IAS 2023; a separate registration is required for the main event.
See full event description here.
With support from:
